MBAYX
Price
$14.06
Change
-$0.01 (-0.07%)
Updated
Nov 13 closing price
RLBGX
Price
$36.66
Change
-$0.04 (-0.11%)
Updated
Nov 13 closing price
Ad is loading...

MBAYX vs RLBGX

Header iconMBAYX vs RLBGX Comparison
Open Charts MBAYX vs RLBGXBanner chart's image
MassMutual Balanced Svc
Price$14.06
Change-$0.01 (-0.07%)
VolumeN/A
CapitalizationN/A
American Funds American Balanced R6
Price$36.66
Change-$0.04 (-0.11%)
VolumeN/A
CapitalizationN/A
MBAYX vs RLBGX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MBAYX vs. RLBGX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBAYX is a StrongBuy and RLBGX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RLBGX has more cash in the bank: 240B vs. MBAYX (105M). RLBGX pays higher dividends than MBAYX: RLBGX (2.55) vs MBAYX (1.43). MBAYX was incepted earlier than RLBGX: MBAYX (27 years) vs RLBGX (16 years). RLBGX is a more actively managed with annual turnover of: 171.00 vs. MBAYX (155.00). MBAYX has a lower initial minimum investment than RLBGX: MBAYX (0) vs RLBGX (250). RLBGX (25.18) and MBAYX (24.16) have marching annual gain over last year. RLBGX return over 5 years is better than : 39.71 vs. MBAYX (16.14).
MBAYXRLBGXMBAYX / RLBGX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence27 years16 years-
Gain YTD16.40616.062102%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets105M240B0%
Annual Yield % from dividends1.432.5556%
Returns for 1 year24.1625.1896%
Returns for 3 years-8.1112.89-63%
Returns for 5 years16.1439.7141%
Returns for 10 years19.9356.2735%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARGX593.955.01
+0.85%
argenx SE
HMST11.56-0.04
-0.34%
HomeStreet
IGT20.98-0.42
-1.96%
International Game Technology PLC
MI8.20-0.34
-3.99%
NFT Limited
ARQT10.25-0.59
-5.44%
Arcutis Biotherapeutics